Q3 EPS Estimate for Globus Medical Boosted by Analyst

Key Points

• Zacks Research raised Globus Medical’s Q3 2026 EPS estimate to $1.19 from $1.18 and maintained a “Strong Buy” rating. The full-year consensus estimate is $4.99 per share.
• Globus Medical recently reported adjusted quarterly EPS of $1.34, beating expectations of $1.10, while revenue rose 5.9% year over year to $789.61 million. The company reaffirmed FY2026 guidance of $4.95–$5.05 EPS.
• The stock opened at $82.95, with analysts carrying a “Moderate Buy” consensus rating and an average price target of $99.46. Institutional investors own 95.16% of shares, while two directors recently sold stock.

Globus Medical, Inc. (NYSE:GMED - Free Report) - Research analysts at Zacks Research lifted their Q3 2026 earnings per share (EPS) estimates for Globus Medical in a report released on Thursday, October 29th. Zacks Research analyst Team now expects that the medical device company will post earnings of $1.19 per share for the quarter, up from their prior estimate of $1.18. Zacks Research has a "Strong-Buy" rating on the stock. The consensus estimate for Globus Medical's current full-year earnings is $4.99 per share. Zacks Research also issued estimates for Globus Medical's FY2026 earnings at $4.98 EPS, Q1 2027 earnings at $1.14 EPS, Q2 2027 earnings at $1.34 EPS, FY2027 earnings at $5.07 EPS, Q2 2028 earnings at $1.47 EPS and FY2028 earnings at $5.89 EPS.

Globus Medical (NYSE:GMED - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, beating analysts' consensus estimates of $1.10 by $0.24. The business had revenue of $789.61 million during the quarter, compared to analysts' expectations of $782.88 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The business's revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter last year, the business posted $0.86 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS.

GMED has been the topic of several other research reports. BTIG Research reissued a "neutral" rating on shares of Globus Medical in a research note on Friday, September 18th. Stifel Nicolaus dropped their price target on shares of Globus Medical from $95.00 to $80.00 and set a "hold" rating for the company in a research report on Wednesday, July 8th. Wells Fargo & Company dropped their price target on shares of Globus Medical from $103.00 to $99.00 and set an "overweight" rating for the company in a research report on Friday, August 7th. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Globus Medical in a research note on Friday, October 9th. Finally, Royal Bank Of Canada decreased their price target on shares of Globus Medical from $115.00 to $85.00 and set an "outperform" rating on the stock in a report on Thursday, October 1st. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $99.46.

Globus Medical Stock Up 2.1%

NYSE GMED opened at $82.95 on Friday. The stock has a market cap of $11.14 billion, a price-to-earnings ratio of 21.21, a price-to-earnings-growth ratio of 1.31 and a beta of 0.96. The business has a fifty day moving average of $77.79 and a 200-day moving average of $83.57. Globus Medical has a fifty-two week low of $59.51 and a fifty-two week high of $101.40.

Insider Buying and Selling

In other news, Director James R. Tobin sold 30,000 shares of the stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the completion of the transaction, the director directly owned 15,000 shares in the company, valued at approximately $1,118,700. This represents a 66.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Stephen Zarrilli sold 25,000 shares of the firm's stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the transaction, the director directly owned 25,000 shares of the company's stock, valued at approximately $2,176,000. This represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 18.38% of the company's stock.

Hedge Funds Weigh In On Globus Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of GMED. Washington Trust Advisors Inc. boosted its holdings in Globus Medical by 116.8% during the second quarter. Washington Trust Advisors Inc. now owns 45,006 shares of the medical device company's stock worth $3,556,000 after buying an additional 24,250 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Globus Medical in the 2nd quarter valued at approximately $1,858,000. WCM Investment Management LLC acquired a new position in Globus Medical in the 1st quarter valued at $16,965,000. Public Employees Retirement System of Ohio bought a new stake in Globus Medical during the 2nd quarter valued at approximately $7,941,000. Finally, Congress Asset Management Co. raised its stake in Globus Medical by 6.6% during the 3rd quarter. Congress Asset Management Co. now owns 361,026 shares of the medical device company's stock valued at $27,041,000 after purchasing an additional 22,401 shares during the last quarter. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Globus Medical Company Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.